Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknow...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Dermatol
Autors principals: Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Boguniewicz, Mark, Sher, Lawrence, Gooderham, Melinda J., Beck, Lisa A., Guttman-Yassky, Emma, Pariser, David, Blauvelt, Andrew, Weisman, Jamie, Lockshin, Benjamin, Hultsch, Thomas, Zhang, Qin, Kamal, Mohamed A., Davis, John D., Akinlade, Bolanle, Staudinger, Heribert, Hamilton, Jennifer D., Graham, Neil M. H., Pirozzi, Gianluca, Gadkari, Abhijit, Eckert, Laurent, Stahl, Neil, Yancopoulos, George D., Ruddy, Marcella, Bansal, Ashish
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865265/
https://ncbi.nlm.nih.gov/pubmed/31693077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.3336
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars